Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis
Joseph A. Miccio(Penn State Milton S. Hershey Medical Center), Krishan R. Jethwa(Mayo Clinic), Amol Narang(Johns Hopkins University), Henry S. Park(Yale University), Christopher L. Hallemeier(Mayo Clinic in Arizona), Jill Lacy(Smilow Cancer Hospital), Michael Cecchini(Yale Cancer Center), Kimberly L. Johung(Yale University), Sajid Khan(Yale University), Timil Patel(Yale University), Jeremy Kortmansky(Yale Cancer Center), Salma K. Jabbour(Rutgers, The State University of New Jersey), Ronald R. Salem(Yale University), Wesley J. Talcott(Yale University), Joseph M. Herman(Northwell Health), Stacey Stein(Yale University)
Cited by 13
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Pancreatic Adenocarcinoma, Version 2.2012
|Journal of the National Comprehensive Cancer Network|2012|304